Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 18:45:23 Source:businessViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Verona confirms Serie A status for another year after beating Salernitana
Next:Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
You may also like
- Here comes the char
- China's Guangdong downgrades flood control emergency response
- Benitez sacked by relegation
- Macao announces schedule for election of Chief Executive Election Committee
- California congressman urges closer consultation with tribes on offshore wind
- Chinese tourist arrivals to Cambodia's Angkor up significantly
- 'Ice city' sees booming tourism
- China launches 504
- Student fatally shot, suspect detained at Georgia's Kennesaw State University